1. Alzheimer's disease.

    The Lancet 388(10043):505 (2016) PMID 26921134

    Although the prevalence of dementia continues to increase worldwide, incidence in the western world might have decreased as a result of better vascular care and improved brain health. Alzheimer's disease, the most prevalent cause of dementia, is still defined by the combined presence of amyloid ...
  2. White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network.

    Annals of Neurology 79(6):929 (2016) PMID 27016429 PMCID PMC4884146

    White matter hyperintensities (WMHs) are areas of increased signal on T2-weighted magnetic resonance imaging (MRI) scans that most commonly reflect small vessel cerebrovascular disease. Increased WMH volume is associated with risk and progression of Alzheimer's disease (AD). These observations a...
  3. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

    Alzheimer's & Dementia 12(3):292 (2016) PMID 27012484

    During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence o...
  4. Two Novel Psychomotor Tasks in Idiopathic Normal Pressure Hydrocephalus.

    International Neuropsychological Society. Journal 22(3):341 (2016) PMID 26817685

    Idiopathic normal pressure hydrocephalus (INPH) is a neurological disorder presenting with gait, cognitive, and bladder symptoms in the context of ventricular enlargement. Although gait is the primary indicator for treatment candidacy and outcome, additional monitoring tools are needed. Line Tra...
  5. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.

    JAMA Neurology 72(11):1324 (2015) PMID 26414022

    Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodro...
  6. Lowering the Floor on Trail Making Test Part B: Psychometric Evidence for a New Scoring Metric.

    Archives of Clinical Neuropsychology 30(7):643 (2015) PMID 26164816

    The Trail Making Test Part B (TMT-B) is widely used in clinical and research settings as a measure of executive function. Standard administration allows a maximal time score (i.e., floor score) of 300 s. This practice potentially masks performance variability among cognitively impaired individua...
  7. Understanding Conflicting Neuropathological Findings in Patients Clinically Diagnosed as Having Alzheimer Dementia.

    JAMA Neurology 72(10):1106 (2015) PMID 26302229

  8. Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer's disease.

    Neurobiology of Aging 36(10):2709 (2015) PMID 26233262

    Disruption in cholinergic neurotransmission is one of the earliest neuropathological changes in preclinical Alzheimer's disease (AD) and may be associated with abnormal beta-amyloid (Aβ) accumulation. Therefore, disruption of cholinergic neurotransmission with scopolamine may unmask otherwise un...
  9. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

    Neurology 85(8):692 (2015) PMID 26208959 PMCID PMC4553028

    To evaluate the effects of bapineuzumab on brain β-amyloid (Aβ) burden using (11)C-Pittsburgh compound B ((11)C-PiB)-PET. Two phase 3 clinical trials, 1 each in apolipoprotein APOE ε4 carriers and noncarriers, were conducted in patients with mild to moderate Alzheimer disease dementia. Bapineuzu...
  10. Biomarkers, assays, and therapies for Alzheimer disease.

    Clinical Chemistry 61(7):903 (2015) PMID 26015517

  11. Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network.

    Brain 138(Pt 4):1036 (2015) PMID 25688083 PMCID PMC4963801

    Prior studies indicate psychiatric symptoms such as depression, apathy and anxiety are risk factors for or prodromal symptoms of incipient Alzheimer's disease. The study of persons at 50% risk for inheriting autosomal dominant Alzheimer's disease mutations allows characterization of these sympto...
  12. Building a roadmap for developing combination therapies for Alzheimer's disease.

    Expert Review of Neurotherapeutics 15(3):327 (2015) PMID 25708309 PMCID PMC4608368

    Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases. A growing number of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treatin...
  13. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

    JAMA Neurology 72(3):287 (2015) PMID 25622185

    In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist in the clinical assessment of suspected Alzheimer disease. To determine the sensitivity and specificity of positron emission tomography imaging with flutemetamol injection labeled with radioactive fluorine 18 to dete...
  14. Charting a path toward combination therapy for Alzheimer's disease.

    Expert Review of Neurotherapeutics 15(1):107 (2015) PMID 25540951

    It is acknowledged that progress in combined therapeutic approaches for Alzheimer's disease (AD) will require an unprecedented level of collaboration. At a meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition and the Critical Path Institute, investigators from in...
  15. Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

    JAMA Neurology 71(9):1111 (2014) PMID 25069482 PMCID PMC4240274

    Autosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 specific genes in contrast to late-onset Alzheimer disease (LOAD), which has a more polygenetic risk profile. To assess the similarities and differences in functional connectivity changes owing to ADAD and LOAD....
  16. AMYLOID BURDEN-RELATED PERFORMANCE DIFFERENCES ON COGNITIVE AND FUNCTIONAL INSTRUMENTS ACROSS ALZHEIMER'S DISEASE PATHOPHYSIOLOGIC STAGES

    Alzheimer's & Dementia 10(4):P839 (2014)

  17. THE DIAN-TU

    Alzheimer's & Dementia 10(4):P247 (2014)

  18. VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION

    Alzheimer's & Dementia 10(4):P546 (2014)

  19. VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION

    Alzheimer's & Dementia 10(4):P60 (2014)

  20. EVIDENCE OF NEUROINFLAMMATION IN THE RETINA IN PRESYMPTOMATIC ALZHEIMER'S DISEASE

    Alzheimer's & Dementia 10(4):P429 (2014)